New Alzheimer's Drug Slows Disease Progression by 45% in Phase III Trial
The largest Alzheimer's drug trial in history has reported a 45% slowing of disease progression, marking the most significant advance in dementia treatment in decades.
By Good News Hero Team
In results described by researchers as "a turning point in Alzheimer's history," a new drug called donanemab has demonstrated a 45% slowing of disease progression in the largest Phase III clinical trial ever conducted for an Alzheimer's treatment.
The trial enrolled 1,736 patients with early symptomatic Alzheimer's across 24 countries. After 18 months, patients receiving donanemab showed significantly slower cognitive decline on every measured scale compared to those receiving a placebo.
"We've gone from treating symptoms to actually modifying the disease," said Dr. Rachel Thompson, lead investigator. "For patients in early stages, this could mean years more of independence and quality of life."
The largest Alzheimer's drug trial in history has reported a 45% slowing of disease progression, marking the most significant advance in dementia treatment in decades.
The drug works by targeting and clearing amyloid plaques from the brain — the protein deposits long suspected as a key driver of Alzheimer's. Regulatory applications have been filed with the FDA and EMA, with approval expected within 12-18 months.
More than 55 million people worldwide live with Alzheimer's or related dementias. Researchers estimate that if widely deployed, donanemab could delay the need for full-time care by an average of 4-5 years for early-stage patients.
